A study by Oklahoma University suggested that ZIP4 could increase the resistance of pancreatic cancer patients to gemcitabine by upregulating the expression of ITGB1, which was associated with a poor prognosis (51). The gene discussed is ITGB1; the disease is pancreatic neoplasm.